Secondary Logo

Institutional members access full text with Ovid®

Daily coffee consumption and prevalence of nonmelanoma skin cancer in Caucasian women

Abel, Ernest L.a b; Hendrix, Susan O.a c; McNeeley, S. Genea c; Johnson, Karen C.d; Rosenberg, Carol A.e; Mossavar-Rahmani, Yasminf; Vitolins, Marag; Kruger, Michaela b

European Journal of Cancer Prevention: October 2007 - Volume 16 - Issue 5 - p 446-452
doi: 10.1097/01.cej.0000243850.59362.73
Research papers: Skin Cancer

The purpose of this study was to assess the relationship between daily coffee consumption and nonmelanoma skin cancer. This study was a cross-sectional analysis of women enrolled in the Women's Health Initiative Observational Study (n=93 676). As nearly all cases of self-reported nonmelanoma skin cancer occurred among Caucasian women (97.8%), we focused our analyses on this group. Compared with nondrinkers, women drinking only caffeinated coffee on a daily basis had a 10.8% lower prevalence of nonmelanoma skin cancer. Consumption of six or more cups of caffeinated coffee per day was associated with a 36% reduction in nonmelanoma skin cancer. After adjusting for various demographic and life style variables, daily consumption of six or more cups was associated with a 30% reduced prevalence of nonmelanoma skin cancer. In contrast to caffeinated coffee, daily consumption of decaffeinated coffee was not associated with a significant change in self-reported nonmelanoma skin cancer for Caucasian women. Daily caffeinated coffee consumption was associated with a dose-related decreased prevalence of nonmelanoma skin cancer in Caucasian women.

Departments of aObstetrics & Gynecology


cWomen's Health Initiative, Wayne State University, Detroit, Michigan

dUniversity of Tennessee Health Science Center, Memphis, Tennessee

eDepartment of Medicine, Evanston Northwestern Healthcare, Evanston, Illinois

fDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, New York

gDepartment of Public Health Sciences, Wake University School of Medicine, Winston-Salem, North Carolina, USA

Correspondence to Dr Ernest L. Abel, PhD, C.S. Mott Center for Human Growth & Development, 275 E. Hancock, Detroit, MI 48201, USA

Tel: +1 313 577 1068; fax: +1 313 577 8554; e-mail:

Received 25 April 2006 Accepted 28 June 2006

© 2007 Lippincott Williams & Wilkins, Inc.